Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - A European study

Pharmacy World and Science

Volumn 29, Issue 3, 2007, Pages 126-130

  Broekema, W J ^a,b   De Groot, I W ^a   Van Harten, P N ^a  

^a Symfora Group Psychiatric Center   (Netherlands)

^b Medisch Centrum   (Netherlands)

Author keywords

Anticholinergics; Antipsychotic agents; Drug therapy combination; Drug use study; Europe; Pharmaco epidemiology; Polypharmacy

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; BROMPERIDOL; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOTIAPINE; CLOZAPINE; CYAMEMAZINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROCYCLIDINE; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TROPATEPINE; UNINDEXED DRUG; ZOTEPINE; ZUCLOPENTHIXOL;

ALLOPATHY; ARTICLE; BELGIUM; CLINICAL PRACTICE; DENMARK; DRUG COMBINATION; EUROPEAN UNION; FRANCE; FREQUENCY ANALYSIS; GERMANY; HOSPITAL PATIENT; HUMAN; NETHERLANDS; PHARMACIST; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PRESCRIPTION; UNITED KINGDOM;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; EUROPE; FEMALE; HOSPITALS; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY;

EID: 34249875962     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9063-1     Document Type: Article

References (18)

1. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106(5):323-330
2. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatr 2001;46(4):334-9
3. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatr Clin Pract 2000;4(1):41-6
4. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003;17(2):223-9
5. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54(1):55-9
6. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12(1):41-8
7. Grohmann R, Engel RR, Geissler KH, Ruther E. Psychotropic drug use in psychiatric inpatients: Recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004;37(3, suppl 1):27-38
8. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-6
9. Schulz P, Rey MJ, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics. Int Clin Psychopharmacol 1989;4(2):105-14
10. Siegfried SL, Fleischhacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive care of schizophrenia, a textbook of clinical management. London: Martin Dunitz Ltd; 2001. ISBN 1-85317-893-4
11. Atkins M, Burgess A, Bottomly C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psych Bull 1997;21:224-6
12. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatr 1994;55(2):44-9
13. Naber D, Holzbach R, Perro C, Hippius H. Clinical managment of clozapine patients in relation to efficacy and side effects. Br J Psychiatr 1992;160(17, suppl):54-9
14. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective study of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-85
15. Stahl SM. Antipsychotic polypharmacy, part 1: Therapeutic option or dirty little secret? J Clin Psychiatr 1999;60(7):425-6
16. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatr 2004;161(4):700-6
17. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatr 1998;173(10):325-9
18. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatr 2004;161(1):116-24